{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:56:36Z","timestamp":1784919396538,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Serum neurofilament light chain (sNfL) has emerged as a biomarker reflecting neuroaxonal damage. The role of sNfL in predicting clinical outcome and guiding therapeutic management in multiple sclerosis (MS) is an ongoing research topic. We sought to evaluate sNfL utility for the prediction of achieving No Evidence of Disease Activity-3 (NEDA-3) among MS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective cohort study including MS patients with a single sNfL measurement at first clinical evaluation. Follow-up was performed every 6\u00a0months\/clinical relapse and included clinical and MRI evaluation. The main outcome was NEDA-3 achievement during follow-up. sNfL levels were measured, using single-molecule-array (SIMOA) assay. sNfL age- and BMI-normalized Z-scores\u2009&gt;\u20091.5 were defined as high. Linear regression analyses were performed to identify predictors of baseline sNfL Z-score and multivariable Cox proportional hazard regression models were used to evaluate predefined outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 125 patients [age at sNfL measurement:40\u2009\u00b1\u200912, 30% men, 82% relapsing\u2013remitting and 18% progressive MS]:37 treatment-na\u00efve patients, 88 patients under Disease-Modifying-Treatment (DMT) with 19.1 (Interquartile Range:12.1\u201324.5) months median follow-up. Prior DMT use [\u03b2:-0.93; 95%CI:-1.48\u2013 -0.38\n                      <jats:italic>p<\/jats:italic>\n                      -value:0.001] was negatively associated with baseline sNfL Z-scores. Gadolinium-enhancing lesions were associated with higher sNfL Z-scores [adjusted standardized linear regression coefficient-\u03b2:0.68; 95%CI:0.03\u20131.32;\n                      <jats:italic>p<\/jats:italic>\n                      -value:0.036], contrary to T2-weighted lesion activity (\u03b2:0.40; 95%CI:0.17\u20130.94;\n                      <jats:italic>p<\/jats:italic>\n                      -value:0.232). In treatment-naive patients, high sNfL Z-scores were associated with lower probability of achieving NEDA-3 during follow-up [hazard-ratio:0.35; 95%CI:0.13\u20130.96;\n                      <jats:italic>p<\/jats:italic>\n                      -value:0.041].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrated that gadolinium-enhancing lesions, indicative of active inflammation, are associated with elevated sNfL Z-scores, contrary to T2-weighted lesion-activity and highlights the prognostic value of sNfL in achieving NEDA-3 in treatment-naive patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-13709-0","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:42:39Z","timestamp":1773081759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The predictive value of serum neurofilament light chain in achieving no evidence of disease activity-3 (NEDA-3) status in treatment-na\u00efve patients with multiple sclerosis"],"prefix":"10.1007","volume":"273","author":[{"given":"Evangelia Makrina","family":"Dimitriadou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Tzanetakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Theodorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Akrivaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Mastorodemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Maleska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania Alexia","family":"Sotirli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Fakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Stergiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kitsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Giannopapas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Moschovos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Giannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Tzartos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"13709_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100978","volume":"44","author":"MA Rocca","year":"2024","unstructured":"Rocca MA et al (2024) Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis. The Lancet Reg Health - Europe 44:100978. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100978","journal-title":"The Lancet Reg Health - Europe"},{"issue":"10","key":"13709_CR2","doi-asserted-by":"publisher","first-page":"E1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J et al (2019) Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92(10):E1007\u2013E1015. https:\/\/doi.org\/10.1212\/WNL.0000000000007032","journal-title":"Neurology"},{"issue":"22","key":"13709_CR3","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","volume":"89","author":"L Novakova","year":"2017","unstructured":"Novakova L et al (2017) Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology 89(22):2230\u20132237. https:\/\/doi.org\/10.1212\/WNL.0000000000004683","journal-title":"Neurology"},{"key":"13709_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-335831","author":"A Abdelhak","year":"2025","unstructured":"Abdelhak A et al (2025) Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2025-335831","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13709_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13093-1","author":"MS Freedman","year":"2025","unstructured":"Freedman MS et al (2025) The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review. J Neurol. https:\/\/doi.org\/10.1007\/s00415-025-13093-1","journal-title":"J Neurol"},{"key":"13709_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104970","author":"MS Freedman","year":"2024","unstructured":"Freedman MS et al (2024) Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2024.104970","journal-title":"EBioMedicine"},{"issue":"9","key":"13709_CR7","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000003653","volume":"88","author":"J Kuhle","year":"2017","unstructured":"Kuhle J et al (2017) Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 88(9):826\u2013831. https:\/\/doi.org\/10.1212\/WNL.0000000000003653","journal-title":"Neurology"},{"key":"13709_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181577511","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP et al (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology. https:\/\/doi.org\/10.1097\/EDE.0b013e3181577511","journal-title":"Epidemiology"},{"issue":"11","key":"13709_CR9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"key":"13709_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00549-7","author":"SD Newsome","year":"2023","unstructured":"Newsome SD, Binns C, Kaunzner UW, Morgan S, Halper J (2023) No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: clinician and patient perspectives [Narrative Review]. Neurol Ther. https:\/\/doi.org\/10.1007\/s40120-023-00549-7","journal-title":"Neurol Ther"},{"issue":"8","key":"13709_CR11","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","volume":"141","author":"C Barro","year":"2018","unstructured":"Barro C et al (2018) Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141(8):2382\u20132391. https:\/\/doi.org\/10.1093\/brain\/awy154","journal-title":"Brain"},{"issue":"3","key":"13709_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert P et al (2022) Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 21(3):246\u2013257. https:\/\/doi.org\/10.1016\/S1474-4422(22)00009-6","journal-title":"Lancet Neurol"},{"key":"13709_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2025.501928","author":"JM Garc\u00eda Dom\u00ednguez","year":"2025","unstructured":"Garc\u00eda Dom\u00ednguez JM et al (2025) Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. consensus of the Spanish Society of Neurology\u2019s study group on multiple sclerosis and related neuroimmune diseases. Neurolog\u00eda. https:\/\/doi.org\/10.1016\/j.nrl.2025.501928","journal-title":"Neurolog\u00eda"},{"issue":"5","key":"13709_CR14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1352458518765666","volume":"25","author":"N Siller","year":"2019","unstructured":"Siller N et al (2019) Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler J 25(5):678\u2013686. https:\/\/doi.org\/10.1177\/1352458518765666","journal-title":"Mult Scler J"},{"key":"13709_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251335521","author":"E Madill","year":"2025","unstructured":"Madill E et al (2025) Change in serum neurofilament light chain and glial fibrillary acidic protein levels with high-efficacy and low-efficacy early therapy in multiple sclerosis. Mult Scler J. https:\/\/doi.org\/10.1177\/13524585251335521","journal-title":"Mult Scler J"},{"key":"13709_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105988","volume":"92","author":"EM Khedr","year":"2024","unstructured":"Khedr EM, Hassan MM, Shokry AE, Mohamed MS, Ezzeldin MY (2024) 27. Serum neurofilament light chain as a diagnostic marker in drug-naive multiple sclerosis patients: a cross-sectional hospital based study. Mult Scler Relat Disord 92:105988. https:\/\/doi.org\/10.1016\/j.msard.2024.105988","journal-title":"Mult Scler Relat Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13709-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13709-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13709-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:09:41Z","timestamp":1774516181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13709-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["13709"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13709-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the local Ethics Committee of Attikon University Hospital (decision number: \u0395\u0392D318\/29\u201304-2024).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All participants provided signed informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Not applicable. There is no study group involved in our research.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Group Authorship"}}],"article-number":"194"}}